RxDoctor Payments Data

Sarah Hartmann

Gerontology · Saint Louis, MONPI 1881108413

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 28.2% of the total.

$1,665in general payments, 2019–2025

Across 81 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$470
  • Takeda Pharmaceuticals U.S.A., Inc.$337
  • Madrigal Pharmaceuticals$250
  • Regeneron Healthcare Solutions, Inc.$99
  • Aimmune Therapeutics, Inc.$97
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$94
  • plus $318 from 8 others

What the payments were for

  • Food & beverage$1,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,665 in reported general payments places this provider in the 80th percentile of 175 gerontology providers in Missouri.

See all gerontology providers in Missouri

Medicare billing

Part B allowed, 2024
$18,344
Medicare patients
89
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$45,531
Duloxetine Hcl45$1,482
Rosuvastatin Calcium86$1,438
Albuterol Sulfate HfaAlbuterol Sulfate19$1,286
Naltrexone Hcl11$896
Atorvastatin Calcium74$812
Levothyroxine Sodium71$725
Gabapentin35$676
Bupropion XlBupropion Hcl24$566
Losartan Potassium55$399
Alendronate Sodium31$339
Omeprazole28$309
Amlodipine Besylate77$299
Lisinopril61$278
Tamsulosin Hcl14$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$21$45,53143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 gerontology providers in Missouri.

Other gerontology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →